Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-01

Clinical Trial Update: A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) [Phase 1]

View source ↗

Summary

The ASPEN-01 Phase 1 trial of Evorpacept (ALX148) in patients with advanced solid tumors and Non-Hodgkin lymphoma has completed its Phase 1 portion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Evorpacept (ALX148)

Snippet

Sponsor: ALX Oncology Inc. | Conditions: Metastatic Cancer, Solid Tumor | Phase 1 | Status: COMPLETED